Indium (111In) capromab pendetide

Indium (111In) capromab pendetide
Monoclonal antibody
Type Whole antibody
Source Mouse
Target prostatic carcinoma cells
Clinical data
Trade names Prostascint
ATC code V09IB04 (WHO)
CAS Number 151763-64-3 N (capromab)
148805-91-8 (pendetide)
ChemSpider none
 NYesY (what is this?)  (verify)

Indium (111In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer.[1] Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen (PSMA) from prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA.[2] Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single photon emission computed tomography (SPECT).[1]

Early trials with yttrium (90Y) capromab pendetide were also conducted.[3]


  1. 1 2 Manyak, M. J. (2008). "Indium-111 capromab pendetide in the management of recurrent prostate cancer". Expert Review of Anticancer Therapy. 8 (2): 175–122. doi:10.1586/14737140.8.2.175. PMID 18279057.
  2. WHO Drug Information
  3. Kahn, Daniel; J. Christopher Austin; Robert T. Maguire; Sara J. Miller; Jack Gerstbrein; Richard D. Williams (1999). "A Phase II Study of [90Y] Yttrium-Capromab Pendetide in the Treatment of Men with Prostate Cancer Recurrence Following Radical Prostatectomy". Cancer Biotherapy & Radiopharmaceuticals. 14 (2): 99. doi:10.1089/cbr.1999.14.99.

This article is issued from Wikipedia - version of the 8/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.